Plasma Cyclooxygenase-2 as a Potential Biomarker for Early Diagnosis of Kawasaki Disease

Fetal Pediatr Pathol. 2023 Aug;42(4):569-580. doi: 10.1080/15513815.2023.2177129. Epub 2023 Feb 17.

Abstract

Background: Previous research demonstrated the association between cyclooxygenase-2 (COX-2) gene polymorphisms and susceptibility to Kawasaki disease (KD). This study aims to detect the plasma concentration of COX-2 in different phases of KD patients and evaluate the relationship between COX-2 level and coronary artery lesion formation, therapeutic response to intravenous immunoglobulin. Methods: Plasma COX-2 levels were measured by enzyme-linked immunosorbent assay in KD patients during the acute (a-KD, n = 52), subacute (s-KD, n = 46), and convalescent (c-KD, n = 43) phase. Results: The concentration of COX-2 in the a-KD group was significantly higher than that in the s-KD, c-KD, healthy control or febrile control group, respectively. There was no difference in the levels of COX-2 between the KD with or without coronary artery lesion subgroups, intravenous immunoglobulin resistant, and sensitive subgroups in the a-KD group, respectively. Conclusions: The plasma concentration of COX-2 might be a novel potential biomarker of acute KD.

Keywords: Kawasaki disease; coronary artery lesion; cyclooxygenase-2; intravenous immunoglobulin.

MeSH terms

  • Biomarkers
  • Cyclooxygenase 2 / genetics
  • Cyclooxygenase 2 / therapeutic use
  • Early Diagnosis
  • Humans
  • Immunoglobulins, Intravenous / therapeutic use
  • Infant
  • Mucocutaneous Lymph Node Syndrome* / diagnosis
  • Mucocutaneous Lymph Node Syndrome* / genetics

Substances

  • Cyclooxygenase 2
  • Immunoglobulins, Intravenous
  • Biomarkers